Eikon Therapeutics, Inc. (Ticker: EIKN US) is a U.S. biopharmaceutical company specializing in the development of innovative medicines for serious unmet medical needs, with an initial focus on oncology. The company plans to list on the NASDAQ on February 5, 2026, offering 17,648,000 shares at a price range between $16.00 and $18.00. At the midpoint of this range, the IPO is expected to raise approximately $300 million. Eikon Therapeutics targets a valuation of up to $908.2 million.

According to the company, the proceeds from the IPO are intended to advance its clinical pipeline, which includes the mid-to-late stage drug candidate EIK1001. The company utilizes a high-throughput drug discovery platform based on the work of Nobel Prize-winning co-founder Eric Betzig and is led by Dr. Roger M. Perlmutter, a former research chief at Merck. The offering is managed by a bookrunning group including J.P. Morgan, Morgan Stanley, BofA Securities, and Cantor. Since its founding in 2019, the company has reportedly raised over $1 billion from private investors such as Lux Capital and Foresite Capital.